Clinical trials: Irritation
Irritable Bowel Syndrome
Personalized Lifestyle Program in Treatment Resistant Irritable Bowel Syndrome
Patients with treatment resistant irritable bowel syndrome (IBS) are recruited from secondary care gastroenterology clinics in Stockholm and screened for eligibility criteria.
- Trial name
- NCT05028036
- Testing
- Personalized lifestyle treatment program
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Karolinska Institutet
Rectal Hypersensitivity, Irritable Bowel Syndrome-Constipation
SAT vs Escitalopram for Rectal Hypersensitivity
Constipation is a common digestive disorder. After excluding dietary factors, drugs and other secondary causes, at least three broad pathophysiologic subtypes are recognized- dyssynergic defecation, constipation-predominant…
- Trial name
- NCT00584571
- Testing
- Sensory Adaptation Training, Escitalopram Therapy
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Augusta University
IBS - Irritable Bowel Syndrome
Effect of Postbiotic Product on Colonic Barriers in IBS
Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS).
- Trial name
- NCT05475314
- Testing
- ReFerm(R)
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Nordisk Rebalance A/S
Irritable Bowel Syndrome
Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients
Visceral hypersensitivity, low grade inflammation and increased intestinal permeability are three main pathophysiological mechanisms involved in irritable bowel syndrome. The connexion between these abnormalities is not known.
- Trial name
- SIIMPA (NCT02550704)
- Testing
- Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability
- Where
- France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Rouen
Skin Barrier to Water Loss, Skin Health
Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery
This clinical study evaluates a topical botanical formulation for supporting skin recovery following invasive and non-invasive aesthetic procedures.
- Conditions
- Skin Barrier to Water Loss, Skin Health, Skin Discoloration, Skin Irritation
- Trial name
- APC-SKIN (NCT07807085)
- Testing
- Apple Peptide Complex Post-Aesthetic Care Protocol
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Grow Out Oils Clinical Aromatherapy Company
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Bowel Syndrome
Marine Protein Hydrolysate as Dietary Supplement in Irritable Bowel Syndrome
The use of natural bioactive products for prevention and treatment of a wide spectrum of conditions, including gastrointestinal disorders and conditions is well known.
- Trial name
- MPH_IBS (NCT03801057)
- Testing
- MPH_active
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Helse Møre og Romsdal HF
Irritable Bowel Syndrome, Visceral Hypersensitivity
Evaluation of Bowel Sensitivity Threshold in IBS Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag
BACKGROUND \& AIMS: Bowel hypersensitivity (lower threshold for discomfort in response to distention of a balloon in the rectum compared to healthy controls) is a key documented feature in Irritable Bowel Syndrome (IBS)…
- Trial name
- NCT03224494
- Testing
- Rapid Barostat Bag, IBS severity scoring system questionnaire (IBS-SSS), HAD scale questionnaire
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Queen's University
Irritable Bowel Syndrome
Effects of Dietary Fibre in Irritable Bowel Syndrome (IBS)
The aim of the study is to investigate how different dietary fibre combinations affects physiological and microbiological outcomes, in addition to symptoms in those with IBS.
- Trial name
- NCT03803319
- Testing
- Fibre 1 (combined fibres), Fibre 2 (natural fibres)
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- King's College London
Irritable Bowel Syndrome, Stigma
Effect of a Psychological Intervention on Stigma: a Randomized Controlled Study
The purpose of this study was to construct a Stigma intervention program for college students with Irritable Bowel Syndrome (IBS) based on the Acceptance and Commitment Therapy (ACT) theory and to investigate the effectiveness in…
- Conditions
- Irritable Bowel Syndrome, Stigma, Psychological Intervention
- Trial name
- NCT06456710
- Testing
- Conventional IBS Health Education, Based on ACT Theory of Psychological Intervention
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yangzhou University
Irritable Bowel Syndrome
Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects around 5% of the general population and remains a daily problem in clinicians' practices, with inconsistent efficacy of treatments despite patients' high expectations.
- Trial name
- ACALMI (NCT07039747)
- Testing
- treatment with DIELEN® Protect
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Rouen
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome (IBS)
IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome
Background: Irritable Bowel Syndrome (IBS) affects approximately 4.1% of the global population and imposes a significant personal and healthcare burden.
- Trial name
- IBS-CDED (NCT07707635)
- Testing
- Modified Crohn's Disease Exclusion Diet (CDED), Low FODMAP Diet
- Volunteers
- 150 people
- Sponsor
- Ariel University
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome, Constipation
Cognitive Behaviour Therapy for Patients With IBS
Irritable bowel syndrome (IBS) affects approximately 10-15% of the adult population. This condition is characterized by abdominal pain, altered bowel habit, abdominal bloating and reduced quality of life.
- Conditions
- Irritable Bowel Syndrome, Constipation, Abdominal Pain, Depression
- Trial name
- EFI (NCT00788658)
- Testing
- Diet modifications, Cognitive behavioral therapy
- Volunteers
- 100 people
- Sponsor
- Rabin Medical Center
Irritable Bowel Syndrome (IBS)
Feasibility of an Online Cognitive Behavioural Therapy Application (Mahana IBS™, Mahana Therapeutics) in the Management of Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a very common condition where patients suffer from recurrent episodes of tummy pain associated with the way the bowel works (either constipation, diarrhoea, or a mix of both).
- Trial name
- MahanaPilot (NCT07008404)
- Testing
- online cognitive behavioral therapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Irritable Bowel Syndrome, Diarrhea
Fecal Microbiota Transplantation for IBS
The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with…
- Trial name
- NCT05776914
- Testing
- Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Madhusudan (Madhu) Grover, MBBS
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Sunscreening Agents
Evaluation of the Irritation Potential of Products in Human Eyes.
To evaluate the human eye irritation potential of two test sunscreen formulation
- Trial name
- NCT02728856
- Testing
- Sunscreen Spray SPF50 Z15-034(BAY987516), Sunscreen Spray SPF50 Z15-038(BAY987516)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to…
- Trial name
- NCT02419963
- Testing
- endoscopy for tissue biopsy, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.